Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OpGen, Inc.
  6. News
  7. Summary
    OPGN   US68373L3078

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OpGen : Alliance Global Partners Adjusts OpGen PT to $5.65 From $5, Maintains Buy Rating

11/13/2020 | 12:26pm EDT


ę MT Newswires 2020
All news about OPGEN, INC.
09/15OPGEN : Announces Data from Prospective Randomized Controlled Multicenter Clinical Study U..
AQ
09/15OpGen, Inc Announces Clinical Data from Investigator-Initiated and Driven Prospective R..
CI
08/13OPGEN : Note 2 - Going Concern and Management's Plans
AQ
08/13OPGEN : Corporate Presentation (PDF)
PU
08/12OPGEN : Reports Second Quarter 2021 Financial Results and Provides Business Update (Form 8..
PU
08/12OPGEN INC : Results of Operations and Financial Condition, Financial Statements and Exhibi..
AQ
08/12Opgen, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/12OPGEN : Earnings Flash (OPGN) OPGEN Posts Q2 Revenue $811,615
MT
08/12OPGEN : Reports Second Quarter 2021 Financial Results and Provides Business Update
AQ
08/05OPGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on OPGEN, INC.
More recommendations
Financials (USD)
Sales 2021 3,30 M - -
Net income 2021 -38,5 M - -
Net Debt 2021 7,16 M - -
P/E ratio 2021 -2,93x
Yield 2021 -
Capitalization 119 M 119 M -
EV / Sales 2021 38,4x
EV / Sales 2022 11,7x
Nbr of Employees 102
Free-Float 99,7%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,12 $
Average target price 5,00 $
Spread / Average Target 60,3%
EPS Revisions
Managers and Directors
Oliver Schacht Chief Executive Officer & Director
William E. Rhodes Non-Executive Chairman
Vadim Sapiro Chief Information Officer
Faranak Atrzadeh Chief Marketing & Scientific Affairs Officer
Johannes Bacher Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
OPGEN, INC.52.94%119
MODERNA, INC.305.22%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.41.30%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-9.18%28 939